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A faculty with ‘a place in the world’
Founded in 1958, Monash University in Melbourne,
Australia, has a reputation as an international, research-
focused institution. Today, Monash encompasses 55,000
students, 14,000 staff, 10 faculties, and eight campuses
(including campuses in Malaysia and South Africa).
The Faculty of Medicine, Nursing, and Health Sciences
offers the most diverse range of programmes in health and
medicine of any Australian university with over 1,700 staff,
1,500 adjunct staff, and around 6,500 students. It is ranked
in the highest tier among Australian universities for
teaching and learning.
Located at six campuses, the faculty comprises ten
schools (each with multiple departments), 29 teaching and
clinical centres, and two research institutes—the Monash
Institute of Medical Research (MIMR) and the Australian
Regenerative Medicine Institute (ARMI). ARMI is also the
headquarters for Australia’s associate membership of the
European Molecular Biology Laboratory (Fig. 1).
‘From bench to bedside’
The faculty’s strong research reputation is based on key
research themes including regenerative medicine, stem cell
science, cardiovascular disease, cancer, structural biology
and drug development, global infection and immunity,
inflammation, allergy and auto-immunity, and mental health
and cognitive neurosciences.
The faculty places a strong emphasis on translating
research and with sites at major hospitals and clinical
centres throughout Melbourne and rural Victoria. Monash
researchers are ideally positioned to transfer their work
from laboratory to clinic and out into the community.
Partnering for success
Sustained access to top research and development (R & D)
infrastructure is a burden shared by academia and industry.
Staff scientific skills need refreshing and updating on a
frequent basis, and due to technological advances, equipment
is often expensive and of limited lifespan. The cost burden on
small laboratories and small-to-medium-sized enterprises
(SMEs) means that key experimentation and validation steps
are often performed on old instrumentation by poorly trained
staff. Hiring and training staff plus purchasing and acquiring
new equipment affects timeframes. Alternatively, these key
experiments are not done at all. Well-financed organisations
provide more infrastructures, but cannot provide for all
eventualities, and even so, expensive equipment and technol-
ogies, as well as trained staff need to be deployed more
efficiently to maximise capital.
Organising around and investment in platform technologies
provide a cost-effective solution, and Monash has taken the
approach of concentrating technology in key platform areas in
order to support its own researchers and as part of a plan to
engage academic collaborators and industry.
In Australian academia, most research is performed in
small groups with access to a limited range of equipment
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and skills to suit immediate needs with little capacity to
expand into broader areas of related research or to
undertake even moderate scale translational research.
Similarly, small-to-medium biotechnology companies re-
quire access to often sophisticated R & D technology and
expertise without having to hire skilled personnel and
avoiding extensive purchasing and renewal of high tech-
nology infrastructure. Both academic and industrial groups
benefit from access to shared cutting edge infrastructure run
by skilled operators, and which has appropriate access
arrangements, high quality governance, and transparent cost
structures.
Interactions between academia and SMEs are often
characterised by proof of principle data on the academic
side that is too limited to meet the proof of concept needs of
the industry partner. This challenges the willingness of
industry to fund academic science. To accelerate a project
to the proof of concept stage, industry can provide the
infrastructure to build prototypes of the discovery—but this
often comes at the price of lack of involvement in the
ongoing research by the academics, with a concurrent lack
of intellectual engagement and a lower perceived value of
the project to both sides. Alternatively, academia can
provide industrial quality infrastructure to build prototypes
and so, remain more engaged in the R & D process. This
approach using high quality technology platforms benefits
industry through greater intellectual input and improves
value from all points of view.
Partnering with the Government of the State of Victoria,
Monash chose the latter path to add value to its academic
and industrial projects. For example, new drug targets can
be exploited through structure-based design and medicinal
chemistry development. New biotherapies, such as mono-
clonal antibodies and vaccines, can be identified, designed
and manufactured at scales suitable for pre-clinical efficacy,
toxicology testing, and early-scale clinical trials.
In 2001, the Victorian Government launched the Bio-
technology Strategic Development Plan (BSDP)—a three-
year action plan capitalising on the state’s strengths in
biomedical research. The initial focus of the BSDP was on
strengthening Victoria’s R & D sector through significant
investment in infrastructure and capacity building. The
current version of the plan places emphasis on mechanisms
that ensure the capture and translation of discoveries into
practise and products, including measures that focus and
build on human and financial capital.
The Monash cluster is the University’s response to the
State government initiative and forms part to its roadmap
for industry engagement. This cluster is a multi-disciplinary
consortium of centres, schools, institutes, and hospitals,
holding a shared vision to contribute to Victoria’s success
as a research and biotechnology centre (Fig. 2).
Monash’s technology platforms are part of the cluster’s
infrastructure. The desire to develop an inter-operable suite
of technology platforms arises from a belief that complex
problems can be better solved through a multi-disciplinary,
technology-systems approach.
Technology platforms are defined as core facilities or
capabilities that provide high quality specialist services to
the research community, government, and industry. Such
facilities might include genomics (i.e., DNA sequencing
and synthesis), imaging, antibody production, proteomics,
compound library screening, pre-clinical ADME-Tox, and
animal provision. Platforms often evolve from local or
Fig. 2 Monash University, genomics facility
Fig. 1 Monash University,
Clayton campus
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shared infrastructure and develop into consolidated, well-
managed technology capabilities delivering high-quality
service in a timely fashion. Core facilities operating at the
level of a ‘true’ platform are characterised by:
& State-of-the-art equipment;
& Internationally and/or nationally respected operators;
& Standardised and accredited standard operating protocols;
& A reputation for providing the timely delivery of a
quality product or service;
& Highly trained staff, dedicated to the facility, who can
troubleshoot;
& Coordinating and resourcing of the instrument maintenance/
service by formal agreements;
& Advertisement of the capability across the organisation;
and
& Business planning.
Monash currently has 12 recognised technology platforms/
capabilities with three under active development and another
under consideration (Table 1). Other shared infrastructure
within Monash and across Victoria will be identified and
characterised from a comprehensive mapping exercise
funded by the Victorian government. The university has
also developed strong relationships with its affiliated medical
research institutes and hospitals, as well as with the
Commonwealth Scientific and Industrial Research Organisa-
tion and with the Australian Synchrotron.
Monash is now undertaking a more coordinated ap-
proach to the management of its platforms, aiming to
increase scale and to seamlessly consolidate them, enabling
research platform that will operate at world’s best practise.
Integration of these core facilities, with appropriate support,
allows Monash to better engage with its own constituency,
as well as with industry and government, ultimately
providing a first class ‘one stop technology shop’.
Operating an integrated suite of technology platforms
promises a number of benefits, including:
& Greater coordination of shared infrastructure, with a
common management and governance structure enabling
better integration of services (technology pipeline);
& Improved access to publicly funded, shared infrastructure
through centralisation and consolidation of services, and
building awareness through a commonmarketing strategy;
& A universal quality plan that mandates key performance
indicators, annual reporting, and periodic review;
& Efficiency gains through the opportunity for centralised
administrative support;
Table 1 Partial catalogue of technology platforms Monash University. Operational platforms are shaded green, while those under development
are shaded orange
Platform Description
Centre for Drug Candidate Optimisation Lead candidate optimisation in support of emerging drug discovery programmes
Centre for Green Chemistry Cleaner synthesis technology, green biotechnology
FlowCore Flow cytometry
Micromon (genomics) DNA sequencing and synthesis
Monash Antibodies Technology Facility Production of monoclonal antibodies
Monash Animal Research Platform Provision of animals for research and teaching
Monash Centre for Electron Microscopy Detailed imaging of small particles
Monash Institute in pharmaceutical sciences Drug candidates for preclinical and clinical development
Monash microimaging Optical imaging and EM
Protein production unit Cloning, expression and purification of proteins
Proteomics Basic protein characterisation
Victorian Bioinformatics Consortium Bioinformatics research and support
FishCore Zebrafish models for disease
Bioimaging Biomedical imaging (e.g., PET and MRI)
Structural biology Protein crystallisation and determination of structure
Fig. 3 Monash University, protein production facilities
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& Attracting larger value, longer term research grants, and
industry funding through the collaboration of key
researchers and research groups;
& Improved capacity to attract more government funding
to maintain and expand these platforms; and
& Provision of training opportunities for under-graduate
and graduate students at the academic/industrial inter-
face (Fig. 3).
The university provides the platforms with support
services, such as human resources, finance, business
development, and information technology departments in
order to help integrate each of the platforms. HR ensures
that the staff working through the platforms are appropriately
rewarded. Finance assists with budgeting, project manage-
ment, accounting, and contract management. Business
development facilitates industry engagement, commerciali-
sation, IP protection, business planning, marketing, and
contract development. And information technology enables
cross-platform linkages, process flow, project management,
and sales and marketing.
A considerable benefit of technology platforms comes from
harnessing their combined capabilities. Hence, through coor-
dinated management and integration of core capabilities,
Monash offers access to a technology ‘pipeline’ or ‘mega-
platform’. Participating platforms provideMonash researchers,
academic collaborators, affiliated institutions, and the pharma-
ceutical and biotechnology industries access to a one stop
technology shop.
A proposal for the development of a therapeutic mono-
clonal antibody can be taken from high throughput antigen
design, production, purification, and characterisation through
to immunisation of mice, selection of hybridomas at high
throughput, screening for bioactivity, conversion to humanised
formats, scale up, purification and characterisation, evaluation
in animal models of disease, ADME and toxicology studies in
large animal models, and preparation for clinical trials.
Similarly, research and development of small molecule drug
candidates or candidate vaccines can be pursued through a
complementary and partially overlapping suite of platforms.
Independently of the concept being tested, candidate
therapeutic and technology ‘trains’ based on small molecule
drug targets, therapeutic antibodies and vaccines, and other,
as yet, undefined projects can be developed by stopping at
appropriate platforms with project management keeping
them on the rails. This model of early R & D is entirely
conventional in industry. When coupled with the imagina-
tive environment of the modern day university, it will
produce exciting new medicines and therapies by better
connecting academia to industry.
As detailed in later chapters, the Monash platform
technologies underpin a significant component of the
universities research outputs. For example, the work of
Professor Rossjohn and his colleagues is critically depen-
dent on access to high throughput crystallisation technolo-
gies, as well as easy access to a high quality synchrotron
technology. Using these technologies, Professor Rossjohn
and his team have provided new and unique insights into
the impact post-translational modifications on T cell
epitopes have on immune recognition and potential immu-
notherapies [1]. Access to unique transgenic mouse models,
bioinformatics, and coupled with high end genomic
technologies have allowed Professor Bryan Williams and
colleagues at the MIMR to examine how specific transcrip-
tion factors play a critical role in immunity and cancer [2].
In the Monash and Immunology Stem Cell Laboratories
(MISCL), Professor Richard Boyd and his group have
utilised a number of the Monash platform technologies,
including monoclonal antibody production and flow cytom-
etry in their work examining the nexus between stem cells
and the immune system [3].
The end game of this research is to bring the promise of
stem cell therapies even closer to the clinic. Finally, in
studies to examine the sources and targets of oxidative
stress, Professor Harald Schmidt and colleagues will use
specific antibodies developed in the Monash Antibodies
Technology Facility to characterise NADPH oxidases
(NOX), which are a critical component in the production
of damaging reactive oxygen species in the vasculature [4].
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